Answers are grounded in this paper and cite their sources.
MGPT TP53+ individuals differ in phenotype from those ascertained through SGT and are notably older at cancer diagnosis and less likely to meet LFS clinical criteria. These findings suggest that LFS may have a greater phenotypic spectrum than previously appreciated. This has implications for the counseling of MGPT TP53+ individuals. Prospective follow-up of these individuals and families is needed to re-evaluate cancer risks.
No takes yet. Share an insight, caveat, or question.
Rana et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: